PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Anhui New Star Pharmaceutical Development Co., Ltd

USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2017–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Anhui ranks #44,719 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.

#44,719
of 49,997 US assignees by volume
17th percentile
by Innovation Score (25.2/100)
8.8
avg claims per patent
-33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R44719 · Foreign Corporation #44,719 · 5 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MICRO 5 grants
  • LOWER-Q #44,719/49,997
  • PHOTO-FINISH Anchor Innovation…
  • CPC-NARROW C07D · 4 areas
  • INNOV-THIN 25.2/100
  • CLAIMS-PAR 8.8 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DOWN -33% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Anchor Innovation Medical, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Anhui

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Anhui's Innovation Score is 25.2/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Anhui's grants concentrate

Anhui New Star Pharmaceutical Development Co., Ltd is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (3 grants) versus a trough of 1 in 2021. By volume, Anhui sits between Anchor Innovation Medical, Inc. and Anji Microelectronics (Shanghai) Co. Ltd.

Anhui's three-year grant acceleration

Anhui New Star Pharmaceutical Development Co., Ltd shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Anhui's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Anhui holds 5 patents at rank #44,879, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Anhui

By rank, the assignees closest to #44,879 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Anhui's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Anhui, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (25 here).

Poulsen Roser A/S 25 Tokyo Medical University 25 Dasman Diabetes Institute 25 Quantum Genomics 25

Anhui's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 17th percentile higher than 17% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 201720212022 1
USPTO utility patent grants by year · 2017–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Anhui New Star Pharmaceutical Development Co., Ltd patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 3 60.0%
2021 1 20.0%
2022 1 20.0%

Which technologies does Anhui New Star Pharmaceutical Development Co., Ltd patent most?

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#44,719

of 49,997 tracked assignees

Innovation Score

25.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Anhui New Star Pharmaceutical Development Co., Ltd's patent record in context - here's where to go next.

  • Anhui New Star Pharmaceutical Development Co., Ltd's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
  • Ranked #44,719 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Anhui New Star Pharmaceutical Development Co., Ltd against Anchor Innovation Medical, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 25.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.